|
Myeloid Leukemia, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interferon-α2b is FDA approved drug for the treatment of chronic HCV and HBV, melanoma, AIDS-related KS, carcinomas, hairy cell leukemia and chronic myelogenous leukemia.
|
31612813 |
2020 |
|
Myeloid Leukemia, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
An 11-year-old male was diagnosed with chronic-phase chronic myeloid leukemia (CML) in 1998 and received therapy with interferon-α2b and low-dose cytarabine.
|
27434016 |
2016 |
|
Myeloid Leukemia, Chronic
|
0.400 |
Therapeutic
|
disease |
CTD_human |
A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML).
|
12620292 |
2003 |
|
Myeloid Leukemia, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hematological and cytogenetic response of interferon alpha 2b alone and combined interferon alpha plus cytarabine as a first-line treatment in chronic myeloid leukemia.
|
10985480 |
2000 |
|
Myeloid Leukemia, Chronic
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013.
|
10715301 |
2000 |
|
Myeloid Leukemia, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
The patient was treated with Busulphan, alpha-2a interferon, hydroxyurea, and cytosine arabinoside at various times in the course of the chronic phase of CML, because he had no HLA-identical donor for bone marrow transplantation.
|
10087949 |
1999 |
|
Myeloid Leukemia, Chronic
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Efficacy and toxicity of IFN-alpha2b combined with cytarabine in chronic myelogenous leukaemia.
|
10520005 |
1999 |
|
Myeloid Leukemia, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation.
|
9326220 |
1997 |
|
Myeloid Leukemia, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interferon-alpha 2a therapy in CML: disappearance of BCR/ABL transcript in a case of long-lasting continuous cytogenetic conversion.
|
7896213 |
1995 |
|
Myeloid Leukemia, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this paper we have performed the molecular studies of IFNA and IFNB genes in chronic myeloid leukemia (CML) in order to determine if the deletions of these genes are prevalent in this pathology.
|
7544849 |
1995 |
|
Myeloid Leukemia, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
The detection of Philadelphia chromosome negative metaphases in long-term bone marrow cultures of the peripheral blood from patients with chronic myeloid leukemia predicts response to interferon-alpha 2a.
|
1453769 |
1992 |
|
Myeloid Leukemia, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha-2b alone or in combination with interferon gamma.
|
1932740 |
1991 |
|
Myeloid Leukemia, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated the effects of brief (2 h) and continuous exposure to recombinant interferon-alpha (2a) (rIFN-alpha) on the proliferation of primitive (blast colony-forming cells, Bl-CFC) and committed myeloid progenitor cells (BFU-E and GM-CFC) derived from blood and bone marrow of patients with chronic myeloid leukaemia (CML) and normal subjects.
|
2004017 |
1991 |
|
Myeloid Leukemia, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
The maintenance of busulphan-induced remissions in chronic granulocytic leukaemia with recombinant interferon alpha-2b.
|
2372493 |
1990 |
|
Myeloid Leukemia, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration.
|
3165298 |
1988 |
|
Myeloid Leukemia, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
We conclude that while the bcr-abl fusion gene and its transcript undoubtedly play key roles in the pathogenesis of CML, the antiproliferative effect of IFN alpha 2 in CML cell lines relies upon genetic mechanisms other than modulation of bcr-abl expression.
|
3479248 |
1987 |
|
Myeloid Leukemia, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia.
|
3457264 |
1986 |